Anti-PD-1 antibodies and methods of use thereof
The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
1. An isolated polynucleotide encoding a heavy and/or light chain variable region of an antibody that specifically binds to human PD-1, wherein the antibody comprises a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, and 7, respectively; and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.
2. The isolated polynucleotide of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 17; and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 16.
3. The isolated polynucleotide of claim 1 , wherein the polynucleotide encodes an antibody heavy chain and/or an antibody light chain comprising the amino acid sequences of SEQ ID NO: 53 and 19, respectively.
4. A vector comprising the isolated polynucleotide of claim 1 .
5. A recombinant host cell comprising the isolated polynucleotide of claim 1 .
6. A method of producing an antibody that binds to human PD-1, the method comprising culturing the host cell of claim 5 so that the polynucleotide is expressed and the antibody is produced.
7. A method of increasing T cell activation in response to an antigen in a subject, the method comprising administering to the subject an effective amount of an antibody that specifically binds to human PD-1, the antibody comprising a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, and 7, respectively; and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.
8. The method of claim 7 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17; and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16.
9. The method of claim 7 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 53; and a light chain comprising the amino acid sequence of SEQ ID NO: 19, respectively.
10. A method of treating cancer in a subject, the method comprising administering to the subject an effective amount of an antibody that specifically binds to human PD-1, the antibody comprising a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, and 7, respectively; and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.
11. The method of claim 10 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17; and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 16.
12. The method of claim 10 , wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 53; and a light chain comprising the amino acid sequence of SEQ ID NO: 19, respectively.
13. The method of claim 10 , wherein the cancer is selected from the group consisting of acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, bladder cancer, bone cancer, brain stem glioma, breast cancer, cancer of the adrenal gland, cancer of the endocrine system, cancer of the kidney or ureter, cancer of the parathyroid gland, cancer of the small intestine, cancer of the thyroid gland, cancer of the urethra, cancers of the anus, cancers of the oropharynx, cancers of the penis, cancers of the rectum, cancers of the vagina, cancers of the vulva, cancers that express PD-L 1 , carcinoma of the cervix, carcinoma of the endometrium, carcinoma of the fallopian tubes, carcinoma of the renal pelvis, cervical cancer, chronic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal cancer, endometrial cancer, environmentally induced cancers including those induced by asbestos, epidermoid cancer, esophageal cancer, glioblastoma multiforme, glioma, head and neck cancer, hepatocellular cancer, Hodgkin's Disease, HPV-associated cancers, Kaposi's sarcoma, leukemia, liver cancer, lung cancer, lymphocytic lymphoma, lymphoma, melanoma, metastatic cancers, multiple myeloma, neoplasm of the central nervous system (CNS), non-Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, pituitary adenoma, primary CNS lymphoma, prostate cancer, refractory or recurrent malignancies, renal cell carcinoma, sarcoma, sarcoma of soft tissue, skin cancer, solid tumors of childhood, spinal axis tumor, squamous cell cancer, stomach cancer, T-cell lymphoma, testicular cancer, and uterine cancer.
14. The method of claim 10 , wherein the antibody is administered subcutaneously, intratumorally, or intravenously.
15. The method of claim 10 , further comprising administering an additional therapeutic agent to the subject.
16. The method of claim 15 , wherein the additional therapeutic agent is a chemotherapeutic, radiotherapeutic, or checkpoint targeting agent.
17. The method of claim 16 , wherein the checkpoint targeting agent is selected from the group consisting of an antagonist anti-PD-1 antibody, an antagonist anti-PD-L1 antibody, an antagonist anti-PD-L2 antibody, an antagonist anti-CTLA-4 antibody, an antagonist anti-TIM-3 antibody, an antagonist anti-LAG-3 antibody, an antagonist anti-CEACAM1 antibody, an antagonist anti-TIGIT antibody, an agonist anti-CD137 antibody, an agonist anti-ICOS antibody, an agonist anti-GITR antibody, and an agonist anti-OX40 antibody.
18. The method of claim 15 , wherein the additional therapeutic agent is an inhibitor of indoleamine-2,3-di oxygenase (IDO).
19. The method of claim 18 , wherein the inhibitor is selected from the group consisting of epacadostat, F001287, indoximod, and LG919.
20. A host cell comprising:
(a) a first isolated polynucleotide encoding an antibody heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein CDRH1, CDRH2, and CDRH3 comprise the amino acid sequences of SEQ ID NOs: 1, 2, and 7, respectively; and
(b) a second isolated polynucleotide encoding an antibody light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 4, 5, and 6, respectively.
21. The host cell of claim 20 , wherein:
(a) the first isolated polynucleotide encodes an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 17; and
(b) the second isolated polynucleotide encodes an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO: 16.
22. The host cell of claim 20 , wherein:
(a) the first polynucleotide encodes an antibody heavy chain comprising the amino acid sequence of SEQ ID NO: 53; and
(b) the second polynucleotide encodes an antibody light chain comprising the amino acid sequence of SEQ ID NO: 19.
23. A method of producing an antibody that binds to human PD-1, the method comprising culturing the host cell of claim 20 so that the polynucleotide is expressed and the antibody is produced.
24. A method of producing an antibody that binds to human PD-1, the method comprising culturing the host cell of claim 21 so that the polynucleotide is expressed and the antibody is produced.
25. A method of producing an antibody that binds to human PD-1, the method comprising culturing the host cell of claim 22 so that the polynucleotide is expressed and the antibody is produced.